全球生物可吸收支架市场规模、份额和趋势分析报告 – 行业概况和 2032 年预测

生物可吸收支架市场分析

生物可吸收支架市场在创新材料和精密制造的推动下取得了重大进展。药物洗脱生物可吸收支架等最新技术使用聚乳酸 (PLA)等聚合物进行药物控制释放，以防止再狭窄。血管内超声 (IVUS)和光学相干断层扫描 (OCT)等先进成像技术正在提高支架置入的准确性和监测能力。

3D 打印彻底改变了支架原型设计，实现了优化生物降解性和机械强度的定制设计。此外，采用镁合金的混合生物可吸收支架可提供更好的径向支撑和快速吸收。人工智能驱动的分析可用于针对特定患者的支架选择和程序规划，从而提高治疗效果。

与传统金属支架相比，生物可吸收支架能够最大程度地减少炎症和血栓等长期并发症，因此其使用量正在不断增长。它们越来越多地用于治疗冠状动脉疾病，尤其是年轻患者，以在吸收后恢复自然血管功能。

心血管疾病患病率上升、技术进步和政府支持微创解决方案的举措推动了市场增长。新兴市场（尤其是亚太地区）由于医疗保健投资增加和患者意识增强，提供了有利可图的机会。

生物可吸收支架市场规模

2024 年全球生物可吸收支架市场规模为 5.1089 亿美元，预计到 2032 年将达到 11.4882 亿美元，2025 年至 2032 年预测期内的复合年增长率为 10.66%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

生物可吸收支架市场趋势

“药物洗脱生物可吸收支架的采用率不断提高”

生物可吸收支架市场的一个主要趋势是人们对药物洗脱生物可吸收支架的偏好日益增长。这些支架旨在释放治疗剂，降低再狭窄风险，同时在达到其目的后逐渐溶解。它们能够改善血管愈合并避免与永久支架相关的长期并发症，推动了它们的采用。例如，雅培的 Absorb GT1 生物可吸收血管支架系统因提供药物洗脱特性以及随着时间的推移被人体完全吸收而备受关注。这一趋势与向先进的、以患者为中心的医疗技术的广泛转变相一致，促进了市场增长，特别是在冠状动脉疾病发病率高的地区。

报告范围和生物可吸收支架市场细分        

生物可吸收支架市场定义

生物可吸收支架是一种医疗设备，主要用于心血管治疗，用于打开阻塞或狭窄的动脉，然后随着时间的推移自然溶解在体内。这些支架由聚乳酸或镁合金等材料制成，可在愈合过程中支撑动脉，降低与永久性金属支架相关的长期并发症风险，如炎症或再狭窄。生物可吸收支架在数月至数年内降解，具体取决于其成分，不会留下任何永久性异物。它们对年轻患者或需要未来干预的患者特别有益，可提供更好的灵活性并减少长期抗血小板治疗的需求。

生物可吸收支架市场动态

驱动程序

• 心血管疾病发病率不断上升

心血管疾病，尤其是冠状动脉疾病 (CAD) 的发病率不断上升，是生物可吸收支架市场的重要推动力。根据世界卫生组织的数据，CAD 仍然是全球死亡的主要原因，每年有超过 1790 万人死于该疾病。生物可吸收支架通过提供临时动脉支持并逐渐溶解，降低了再狭窄和血栓形成等长期并发症的风险，提供了一种革命性的解决方案。例如，印度的 CAD 病例显着增加，刺激了对先进治疗方案的需求。医院现在更喜欢使用生物可吸收支架而不是传统的金属支架，以改善患者的治疗效果并最大限度地减少术后干预，从而进一步推动市场采用。

• 患者对微创手术的偏好

对微创手术的需求大大促进了生物可吸收支架在心血管治疗中的应用。这些支架具有在提供临时血管支持后溶解的优势，降低了血栓形成和炎症等长期并发症的风险。患者越来越喜欢这些先进的选择，因为它们可以最大限度地减少术后不适和恢复时间，提高整体满意度。例如，2021 年 3 月，Meril Life Sciences 推出了其自主开发的生物可吸收支架支架 MeRes100。MeRes100 是一种薄结构生物可吸收支架，旨在替代传统的金属支架。这种创新产品通过在体内逐渐溶解，减少长期并发症和进一步干预的需要，同时在冠状动脉疾病患者的康复过程中提供足够的支持，提供了一种有希望的治疗选择。

机会

• Preference for Biocompatible Materials

The growing preference for biocompatible materials in stent manufacturing is creating significant opportunities in the bio-absorbable stent market. These materials, such as polylactic acid and magnesium alloys, promote natural healing while minimizing the risk of inflammatory responses or allergic reactions. For instance, in October 2021, Boston Scientific Corporation unveiled positive results for its Eluvia Drug-Eluting Vascular Stent System at the Vascular InterVentional Advances conference in Las Vegas. The stent system demonstrated impressive clinical outcomes, with higher sustained clinical improvement and superior primary patency rates. This late-breaking trial presentation highlighted the effectiveness of Eluvia in providing long-term vascular support, making it a leading option for treating peripheral artery disease with promising patient outcomes. This trend encourages manufacturers to innovate biocompatible solutions, enhancing market growth while meeting rising demand for safer cardiovascular treatments.

• Initiatives for Improved Cardiovascular Care

Government and non-government programs focusing on cardiovascular disease (CVD) management create significant opportunities in the bio-absorbable stent market. Initiatives like the World Heart Federation’s “Global Hearts Program” aim to reduce the global burden of heart diseases through prevention and treatment strategies. In addition, national campaigns, such as the Million Hearts initiative in the U.S., promote early diagnosis and advanced treatments for CVD. These programs drive healthcare systems to adopt innovative solutions, including bio-absorbable stents, to enhance patient outcomes. Such efforts encourage funding, awareness, and regulatory support, enabling broader adoption of these stents in both developed and emerging markets.

Restraints/Challenges

• Risk of Stent Fracture

The risk of stent fracture significantly hinders the bio-absorbable stent market. Bio-absorbable stents are designed to gradually dissolve in the body, but their material integrity may be compromised over time, leading to potential fracture during or after implantation. This can cause serious complications such as restenosis (re-narrowing of the artery), thrombosis (blood clot formation), or other severe cardiovascular issues. The lack of sufficient long-term data on their stability and the possibility of fractures deter both healthcare professionals and patients from opting for these stents. These concerns, combined with the potential for adverse events, have slowed the adoption of bio-absorbable stents, restricting their growth in the market.  

• Complex Implantation Process

The implantation process for bio-absorbable stents presents a significant challenge due to its technical complexity. Different from conventional metallic stents, bio-absorbable stents require advanced surgical techniques and greater precision during implantation. This increased complexity can make the procedure more time-consuming and demanding for healthcare professionals, limiting its widespread adoption. In addition, the learning curve associated with mastering the implantation process can discourage many physicians from using bio-absorbable stents. Inadequate expertise or technical errors during implantation may lead to complications, increasing the risk for patients. As a result, the intricacies of the procedure contribute to the market’s restraint, hindering the widespread use of bio-absorbable stents in clinical practice.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Bio-Absorbable Stent Market Scope

The market is segmented on the basis of material, product, absorption rate, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Material

• Bioresorbable Polymer-Based Stents
  • PGA
  • PLA
  • Co-Polymer
• Bioresorbable Metallic Stents
• Bioresorbable Natural Material-Based Stents

 Product

• Coronary Stents
• Peripheral Stents
• Stent-Related Implants

 Absorption Rate

• Slow-Absorption Stents
• Fast-Absorption Stents

 Application

• Coronary Artery Disease
• Peripheral Artery Disease

 End User

• Hospitals
• Cardiac Centers
• Specially Clinics/ Clinics
• Others

Bio-Absorbable Stent Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, material, product, absorption rate, application and end user as referenced above.

The countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, U.A.E, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)

Europe is expected to dominate the bio-absorbable stent market due to the growing focus on research and development within the region. Increasing investments in healthcare innovation and advancements in medical technologies are driving the development of bioresorbable stents. Leading research institutions and hospitals are conducting trials to enhance the effectiveness and safety of these stents.

Asia-Pacific is expected to witness significant growth in the bio-absorbable stent market due to the increasing prevalence of cardiovascular diseases (CAD and PAD), along with a large patient pool in the region. Rising healthcare investments, improved medical infrastructure, and growing awareness of advanced stenting technologies further fuel the market expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Bio-Absorbable Stent Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Bio-Absorbable Stent Market Leaders Operating in the Market Are:

• Abbott (U.S.)
• REVA Medical, Inc. (U.S.)
• Elixir Medical Corporation (U.S.)
• KYOTO MEDICAL PLANNING Co., Ltd. (Japan)
• BIOTRONIK (Germany)
• Amaranth Medical, Inc. (U.S.)
• Arterial Remodeling Technologies (France)
• Meril Life Sciences Pvt. Ltd. (India)
• Arterius (U.K.)
• Boston Scientific Corporation (U.S.)
• 480 Biomedical, Inc. (U.S.)
• S3V Vascular Technologies (France)
• QualiMed（德国）
• OrbusNeich (香港)
• 美敦力（爱尔兰）
• STENTYS SA（法国）
• 泰尔茂株式会社 (日本)
• 微创医疗科学有限公司 (中国)
• BD（美国）
• B.Braun Melsungen AG（德国）

生物可吸收支架市场的最新发展

• 2023 年 4 月，BIOTRONIK 宣布在加拿大卫生部批准后，在加拿大商业推出其 Orsiro Mission 药物洗脱支架系统。这款先进的系统旨在增强患有糖尿病和其他疾病的患者的冠状动脉管腔直径。BIOTRONIK 正在用最新一代系统取代原来的 Orsiro 系统，为冠状动脉疾病患者提供更好的性能和治疗选择
• 2022 年 3 月，著名医疗器械公司 S3V Vascular Technologies 宣布计划投资 25 亿印度卢比，在海得拉巴附近的 Telangana 医疗器械园区建造一座最先进的支架制造工厂。该工厂旨在提高支架的生产能力，而支架对于心血管手术至关重要。此举是该公司满足印度对高质量、本地制造的医疗器械日益增长的需求的战略的一部分
• 2022 年 2 月，BIOTRONIK 的 Orsiro 冠状动脉药物洗脱支架 (DES) 采用超薄支柱设计，为心血管治疗树立了新的临床标杆。BIOFLOW-V 试验的最后 5 年数据进一步证实了该支架的卓越安全性，证实了 Orsiro 作为 DES 技术黄金标准的地位。这项研究进一步支持将 Orsiro 用作冠状动脉疾病的可靠长期解决方案
• 2021 年 3 月，Meril Life Sciences 推出了自主研发的生物可吸收支架 MeRes100。MeRes100 是一种薄结构生物可吸收支架，旨在替代传统的金属支架。这种创新产品通过在体内逐渐溶解，减少长期并发症和进一步干预的需要，同时在冠状动脉疾病患者的康复过程中提供足够的支持，提供了一种有希望的治疗选择
• 2021 年 10 月，波士顿科学公司在拉斯维加斯举行的血管介入进展会议上公布了其 Eluvia 药物洗脱血管支架系统的积极结果。该支架系统表现出令人印象深刻的临床效果，具有更高的持续临床改善和卓越的初级通畅率。这项最新的试验报告强调了 Eluvia 在提供长期血管支持方面的有效性，使其成为治疗外周动脉疾病的领先选择，具有良好的患者治疗效果

SKU-47808